Catalog No.
DHH02217
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa-lambda
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BCD-100, CAS: 2093956-19-3
Clone ID
Prolgolimab
Antibodies to watch in 2021, PMID: 33459118
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice, PMID: 33872982
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations., PMID:40507271
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer., PMID:39879779
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab., PMID:39505987
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab., PMID:39367001
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)., PMID:39296979
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions., PMID:35062949
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice., PMID:33872982
Antibodies to watch in 2021., PMID:33459118
For research use only. Not for human or drug use.
